Tscan Therapeutics is trading 25.71% down now at $0.49 after announcing a strategic reorganization on September 2, 2026, including a pause in Phase 3 ALLOHA-2 enrollment due to insufficient capital.
- Plans to cut approximately 75% of its workforce, eliminate internal manufacturing, and redirect resources toward two in-vivo solid-tumor candidates.
- The restructuring is expected to save $55 million through 2027 and extend funding into Q4 2027; broader markets remain mixed.